Intratumoural Immunotherapy and Biotech’s Next Frontiers
Kilder
- Bioworld: Global biologics/drugs approved in 2026 - BioWorld News
- nature.com: Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1 - Nature
- nature.com: Delivering an immune therapy into tumours instead of intravenously reduces adverse effects - Nature
- Fiercebiotech: FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death - Fierce Biotech
- fiercebiotech.com: FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death - Fierce Biotech
- biospace.com: Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study - BioSpace
- biopharmadive.com: Chiesi to buy KalVista in $1.9B deal for rare disease drug - BioPharma Dive
- bioworld.com: Chiesi snags on-demand HAE drug in $1.9B Kalvista buy - BioWorld News
- Biospace: Opinion: Tackling drug resistance must become biotech’s next frontier - BioSpace
- biospace.com: Opinion: Tackling drug resistance must become biotech’s next frontier - BioSpace
- Labiotech: In vivo CAR-T gains momentum as big pharma bets billions - Labiotech.eu
- labiotech.eu: In vivo CAR-T gains momentum as big pharma bets billions - Labiotech.eu
- wikimedia: Photo by Globetrotter19 / Wikimedia Commons / CC BY-SA 4.0
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.